Clinical Commander

Back to dossier
cardio.atrial_flutter.atypical-left-atrial.v1PRODUCTION
cardio.atrial_flutter.atypical-left-atrial.v1

Atypical / scar-mediated / left atrial flutter

cardiologyacutechronicadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm atypical (NON-CTI) flutter — morphology not meeting typical sawtooth criteria + history of LA scar substrate (post-PVI, post-CABG, post-MAZE, post-valve, congenital HD); often coexists with AF

Inputs
2
Actions
0
Advance rule
Set
Advance when

Atypical morphology + scar substrate confirmed

Patient inputs (11)

CHA2DS2-VASc + ablation candidacy

Conduction ratio variable (1:1, 2:1, 3:1) — atypical flutter has more variable AV ratios

Identifies scar substrate; ~30–50% of post-PVI patients develop atypical LA flutter (Patel 2008 PMID 18272844)

Atypical morphology — positive flutter waves II/III/aVF, prominent V1 (mitral isthmus, roof-dependent, or LA-scar circuit) — Saoudi 2001 (PMID 11428013); Aliot 2009 (PMID 19324313)

DOAC + AAD dosing; contrast for 3D mapping/ablation

Reversible cause screen; amiodarone-induced thyroid dysfunction common in this population

LA size, EF, valvular function, prior surgical anatomy review; LA appendage thrombus screen pre-ablation

SBP <90 with flutter RVR → emergent DCCV 100–200 J biphasic (atypical may need higher energy than typical)

AC indication identical to AF

HAS-BLED + ablation peri-procedure bleed risk

LA appendage thrombus exclusion + chamber anatomy for 3D mapping — required pre-LA ablation

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningunstable_atypical_flutter_requires_emergent_dccv_higher_energy
    Atypical flutter with SBP <90, AMS, ongoing ischemia, or pulmonary edema → synchronized DCCV 100–200 J biphasic now (atypical often needs higher energy than typical CTI)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_la_ablation_atrioesophageal_fistula
    Fever + chest pain + new neurologic deficit 2–6 weeks post-LA ablation → emergency surgical evaluation; HIGHER RISK in LA ablation than CTI
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepost_la_ablation_scar_at_recurrence
    Recurrent scar-mediated atrial tachycardia within 3 months of LA ablation — common given complex circuits
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereanticoag_bridging_during_la_ablation
    Periprocedural AC management for LA ablation — continuation vs hold of DOAC, heparin bridge timing, post-procedure resumption window
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereamiodarone_toxicity_pulm_thyroid_or_lft
    New pulmonary infiltrates, thyroid dysfunction (hypo or hyper), or LFT elevation on amiodarone — switch AAD or accept AAD failure → re-ablation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemixed_af_aflutter_conversion_during_treatment
    Conversion from atypical AFL to AF (or AF to AFL) during treatment — mixed substrate present
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Atypical / scar-mediated / left atrial flutter — rate control + AAD (often refractory) + AC + 3D electroanatomic mapping ablation pathway — ACC/AHA 2024 (Joglar PMID 38753446); Aliot 2009 (PMID 19324313)
axis: atypical_flutter_scar_mediated_pathway
Selected axis "Atypical / scar-mediated / left atrial flutter — rate control + AAD (often refractory) + AC + 3D electroanatomic mapping ablation pathway — ACC/AHA 2024 (Joglar PMID 38753446); Aliot 2009 (PMID 19324313)" by default fallback (first axis)
  • metoprolol_tartrate
    first line
    beta_blocker
    5 mg IV q5min × 3 then 25–50 mg PO BID • IV/PO • IV q5min × 3 → PO BID
    triggers: atypical_flutter_with_RVR, no_HFrEF_decompensation
    AVN slowing for atypical flutter (often refractory) — ACC/AHA 2024 (PMID 38753446)
    rxcui 203191
  • amiodarone
    first line
    class_III_AAD
    150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance • IV/PO • load + daily
    triggers: atypical_flutter, structural_heart_disease, HFrEF, scar_mediated_substrate
    Most efficacious AAD for atypical/scar-mediated flutter; preferred over class IC (CAST PMID 1900101) given structural HD; pulm/thyroid/hepatic toxicity — ACC/AHA 2024 (PMID 38753446)
    rxcui 703
  • dofetilide
    second line
    class_III_AAD
    125–500 mcg PO BID per CrCl (REMS — inpatient initiation) • PO • BID
    triggers: amiodarone_toxicity_or_intolerance, rhythm_maintenance, baseline_QTc_<440
    Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 49247
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: CHA2DS2VASc_>=2_men_>=3_women, pre_post_cardioversion, pre_post_LA_ablation, mixed_AF_AFL
    AC same as AF; lifelong AC typical given high mixed AF/AFL coexistence — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978)
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15–50) • PO • once daily
    triggers: CHA2DS2VASc_>=2, apixaban_unavailable
    X-VeRT (PMID 24837375); ROCKET-AF foundational
    rxcui 1114195
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    INR 2–3 • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, DOAC_contraindicated
    Mechanical valve / severe MS — only warfarin (common in post-valve atypical flutter) — ACC/AHA 2024
    rxcui 11289

outpatient playbook — drug actions (2)

  1. 1. continue DOAC lifelong if CHA2DS2-VASc ≥2 or mixed AF/AFL
    rxcui 1364430
    apixaban 5 mg BID per CHA2DS2-VASc • PO • BID
    trigger: Persistent stroke risk OR mixed AF/AFL
    Lifelong AC — ACC/AHA 2024 Class I
  2. 2. continue amiodarone if ablation incomplete
    rxcui 703
    200 mg PO daily • PO • daily
    trigger: AAD-dependent rhythm maintenance
    Lower recurrence than other AAD — ACC/AHA 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Flutter waves NOT meeting typical CTI criteria — positive in II/III/aVF, prominent V1, variable axis; Recurrent atrial flutter after prior AF ablation (PVI), MAZE, CABG, valve, or transplant — scar-mediated reentry; Palpitations / dyspnea / fatigue in patient with prior left atrial intervention or congenital heart disease.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atypical / scar-mediated / left atrial flutter** (cardio.atrial_flutter.atypical-left-atrial.v1).
Scope: Confirm atypical (NON-CTI) flutter — morphology not meeting typical sawtooth criteria + history of LA scar substrate (post-PVI, post-CABG, post-MAZE, post-valve, congenital HD); often coexists with AF

No severity triggers fired against current inputs.

Plan

Regimen axis: **Atypical / scar-mediated / left atrial flutter — rate control + AAD (often refractory) + AC + 3D electroanatomic mapping ablation pathway — ACC/AHA 2024 (Joglar PMID 38753446); Aliot 2009 (PMID 19324313)**.
1. metoprolol_tartrate 5 mg IV q5min × 3 then 25–50 mg PO BID IV/PO IV q5min × 3 → PO BID (beta_blocker, first line) — AVN slowing for atypical flutter (often refractory) — ACC/AHA 2024 (PMID 38753446)
2. amiodarone 150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance IV/PO load + daily (class_III_AAD, first line) — Most efficacious AAD for atypical/scar-mediated flutter; preferred over class IC (CAST PMID 1900101) given structural HD; pulm/thyroid/hepatic toxicity — ACC/AHA 2024 (PMID 38753446)
3. dofetilide 125–500 mcg PO BID per CrCl (REMS — inpatient initiation) PO BID (class_III_AAD, second line) — Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
4. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — AC same as AF; lifelong AC typical given high mixed AF/AFL coexistence — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978)
5. rivaroxaban 20 mg with food (15 mg if CrCl 15–50) PO once daily (DOAC_factor_Xa, first line) — X-VeRT (PMID 24837375); ROCKET-AF foundational
6. warfarin INR 2–3 PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS — only warfarin (common in post-valve atypical flutter) — ACC/AHA 2024

Setting playbook (outpatient) — Long-term post-LA-ablation surveillance, lifelong AC (mixed AF/AFL substrate), AAD continuation if ablation incomplete, recurrence + concomitant-AF screening — ACC/AHA 2024 (PMID 38753446)
7. continue DOAC lifelong if CHA2DS2-VASc ≥2 or mixed AF/AFL apixaban 5 mg BID per CHA2DS2-VASc PO BID — Persistent stroke risk OR mixed AF/AFL (Lifelong AC — ACC/AHA 2024 Class I)
8. continue amiodarone if ablation incomplete 200 mg PO daily PO daily — AAD-dependent rhythm maintenance (Lower recurrence than other AAD — ACC/AHA 2024)

Non-pharmacologic actions:
- Lifestyle: weight, alcohol limit, OSA treatment, exercise (ACC/AHA 2024)
- Vaccinations + secondary prevention bundle (ACC/AHA 2024)
- Annual EP review for repeat ablation consideration if recurrence

AVOID / contraindication checks:
- Flecainide propafenone block if structural heart disease — CAST (PMID 1900101); ACC/AHA 2024 — atypical flutter substrate often structural
- Dofetilide REMS inpatient initiation — ACC/AHA 2024 (PMID 38753446)
- Amiodarone monitor pulm thyroid LFT — ACC/AHA 2024
- Non DHP CCB block if EF lt 40 — ACC/AHA 2024 — common HFrEF in this population
- LA ablation requires thrombus exclusion via TEE or CT — HRS 2007 (PMID 17572388)
- DOAC renal dose adjustment — ESC 2024 (PMID 39050851)

Monitoring

Regimen monitoring:
- telemetry continuous acute — ACC/AHA 2024
- HR target 80-110 pre ablation — ACC/AHA 2024
- QTc serial dofetilide sotalol amiodarone — ACC/AHA 2024
- PFTs TFTs LFTs baseline then q6m on amiodarone — ACC/AHA 2024
- lifelong AC due to mixed AF AFL coexistence — ACC/AHA 2024 Class I
- post-LA-ablation atrioesophageal fistula warning ×6 weeks — HRS 2007 (PMID 17572388)
- post-LA-ablation 4-week ECG + Holter 3-6-12 mo for AF AFL recurrence

Setting (outpatient) monitoring:
- Cardiology q3–6 mo first year then annually (ACC/AHA 2024)
- Holter at 3, 6, 12 mo post-ablation (Aliot 2009)
- Annual TFTs / LFTs / PFTs on amiodarone (ACC/AHA 2024)
- CBC + eGFR q6m on DOAC (ESC 2024)

Follow-up plan: EP for 3D mapping ablation; cardiology q3–6 mo; AC continuation per CHA2DS2-VASc (lifelong given mixed AF/AFL); lifestyle (alcohol, weight, OSA); post-ablation 4-week ECG + Holter at 3/6/12 mo for AF screen
- Close-out criterion: Follow-up booked + ablation pathway entered

Monitoring phase: Telemetry; QTc on dofetilide / sotalol / amiodarone; post-ablation observation for groin hematoma, tamponade, atrioesophageal fistula (LA ablation higher risk than CTI); AC adherence

Disposition

Current setting: outpatient — Long-term post-LA-ablation surveillance, lifelong AC (mixed AF/AFL substrate), AAD continuation if ablation incomplete, recurrence + concomitant-AF screening — ACC/AHA 2024 (PMID 38753446)

Disposition criteria:
- Continue chronic surveillance with this engine; cross-link to cardio.afib.core.v1 if AF predominant

Escalation triggers (move to higher acuity):
- Recurrent atypical flutter despite ablation → repeat 3D EP mapping (Aliot 2009)
- New AF detected → AF management via cardio.afib.core.v1; consider PVI
- Amiodarone toxicity (pulm fibrosis, thyroid, LFT) → switch to dofetilide or repeat ablation — ACC/AHA 2024
- Stroke / TIA on AC → workup + reassess regimen — ACC/AHA 2024

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Atypical flutter with SBP <90, AMS, ongoing ischemia, or pulmonary edema → synchronized DCCV 100–200 J biphasic now (atypical often needs higher energy than typical CTI)
- [LIFE_THREATENING] Fever + chest pain + new neurologic deficit 2–6 weeks post-LA ablation → emergency surgical evaluation; HIGHER RISK in LA ablation than CTI
- [SEVERE] Recurrent scar-mediated atrial tachycardia within 3 months of LA ablation — common given complex circuits

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); ESC 2024 AF (Van Gelder EHJ 2024 PMID 39050851); HRS/EHRA/ECAS 2007 catheter ablation expert consensus (Calkins PMID 17572388); Aliot 2009 ESC EP/HRS expert consensus on VT/AT ablation (PMID 19324313) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 17572388) [PMID:17572388](https://pubmed.ncbi.nlm.nih.gov/17572388/)
- Cited evidence (PMID 19324313) [PMID:19324313](https://pubmed.ncbi.nlm.nih.gov/19324313/)
- Cited evidence (PMID 11428013) [PMID:11428013](https://pubmed.ncbi.nlm.nih.gov/11428013/)

Last reconciled with current guidelines: 2026-05-14.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); ESC 2024 AF (Van Gelder EHJ 2024 PMID 39050851); HRS/EHRA/ECAS 2007 catheter ablation expert consensus (Calkins PMID 17572388); Aliot 2009 ESC EP/HRS expert consensus on VT/AT ablation (PMID 19324313) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 17572388) — PMID:17572388
  • Cited evidence (PMID 19324313) — PMID:19324313
  • Cited evidence (PMID 11428013) — PMID:11428013